CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting
-
Published:2023-03-05
Issue:1
Volume:16
Page:
-
ISSN:1756-8722
-
Container-title:Journal of Hematology & Oncology
-
language:en
-
Short-container-title:J Hematol Oncol
Author:
Huang Qiusha,Zhang Xiao-hui,Liu Delong
Abstract
AbstractDue to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan-T cell surface biomarkers that have been either knocked out or knocked down through genome base- editing technology or by protein expression blockers so that the re-engineered T cells can target T cells without fratricide. We summarized several latest reports on the CAR T cells for the therapy of T cell leukemia /lymphoma from the 2022 ASH Annual Meeting, with latest updates on clinical trials of TvT CAR7, RD-13-01, and CD7 CART.
Funder
Capital Health Research and Development of Special Fund National Key Research and Development Program of China National Natural Science Foundation of China
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Biology,Hematology
Reference8 articles.
1. Hou J-Z, Ye JC, Pu JJ, Liu H, Ding W, Zheng H, Liu D. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol. 2021;14(1):66. 2. Kamiya T, Wong D, Png YT, Campana D. A novel method to generate T-cell receptor–deficient chimeric antigen receptor T cells. Blood Adv. 2018;2(5):517–28. 3. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human. Phase I Trial J Clin Oncol. 2021;39(30):3340–51. 4. Chiesa R, Georgiadis C, Ottaviano G, Syed F, Braybrook T, Etuk A, Zhan H, Gkazi SA, Preece R, Adams S, Thomas R, Awuah A, Gilmour K, Mhaldien L, Chu J, Pinner D, Kubat A, Veys P, Rao K, Lucchini G, O’Connor D, Vora A, Qasim W. Tvt CAR7: phase 1 clinical trial of base-edited "universal” CAR7 T cells for paediatric relapsed/refractory T-ALL. Blood. 2022;140(Supplement 1):4579–80. 5. Zhang X, Zhou Y, Yang J, Li J, Qiu L, Ge W, Pei B, Chen J, Han L, Ren J, Lu P. A novel universal CD7-targeted CAR-T cell therapy for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Blood. 2022;140(Supplement 1):4566–7.
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|